Journey Medical (DERM) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
12 Nov, 2026Financial position and portfolio
2025 net product revenue $61M and adjusted EBITDA $2.9M; cash $25.6M as of June 30, 2026.
Market cap $190M, shares outstanding 28.2M and average volume 185K, with market data as of Oct. 1, 2026.
Five core dermatology brands span rosacea, acne and hyperhidrosis; portfolio includes Emrosi, Qbrexza, Amzeeq, Accutane and Fzilxi.
Prescription dermatology markets targeted total ~$5.8B; products acquired since 2021 contribute over 90% of net revenue.
Emrosi clinical profile
FDA-approved in November 2024 and launched in the U.S. in April 2025; once-daily 40 mg capsule combines 10 mg immediate-release and 30 mg extended-release minocycline.
Two Phase 3 trials showed statistically significant superiority to Oracea and placebo on IGA treatment success and inflammatory lesion reduction at week 16.
Relative to Oracea, IGA treatment success was 61% greater and inflammatory lesion reduction 28% greater; treatment success was 122% and lesion reduction 68% greater than placebo.
Efficacy was observed as early as week 2 versus placebo; key treatment-related adverse events were low and most were mild or moderate, with a safety profile described as similar to placebo.
Three U.S. Orange Book-listed patents were issued, with expected market exclusivity to 2039; Phase 3 data appeared in JAMA Dermatology in March 2025.
Emrosi commercial progress and opportunity
Through July 2026, more than 130,000 prescriptions had been filled and over 4,500 unique providers had prescribed Emrosi.
Payer access covered more than 85% of U.S. commercial lives; quarterly TRx rose from 7,394 in Q2 2025 to 35,882 in Q2 2026.
The sales force covers 87% of oral rosacea dermatology TRx in its territories; 94% of oral rosacea TRx were written in dermatology in 2025.
U.S. rosacea treatment sales were over $1.3B in 2025; Oracea had $252M in prescription sales, and U.S. Emrosi net sales potential was stated to exceed $200M.
Global net sales potential was stated at over $300M; potential international out-licensing is an additional opportunity.
Latest events from Journey Medical
- Emrosi-led growth lifted revenue and adjusted EBITDA, despite going-concern uncertainty.DERM
Q3 2026 - EMROSI's rapid market adoption and clinical superiority are fueling significant growth in dermatology.DERM
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue rose 23% to $18.5M, with Emrosi/EMROSI driving growth and net loss narrowing.DERM
Q2 2026 - Emrosi®'s clinical and commercial success positions it as the leading oral rosacea therapy.DERM
Investor presentation - All director nominees and KPMG as auditors for 2026 were approved; Q&A followed.DERM
AGM 2026 - EMROSI drives rapid growth, with rising revenue, margins, and expanded market access.DERM
A.G.P.'s Annual Virtual Healthcare Conference - Q1 2026 revenue up 21% to $16M, net loss narrows, and EMROSI/Emrosi® expands market access.DERM
Q1 2026 - Q2 revenue rose sequentially, profitability improved, and DFD-29 FDA review is pending.DERM
Q2 2024 - Emrosi FDA approval and launch set the stage for transformational growth in 2025.DERM
Q4 2024